OrbusNeich Medical Group Holdings (6929) Fundamentals 2026 — P/E 9.2x, Revenue Analysis | SniperIQ
OrbusNeich Medical Group Holdings (6929) is a HK-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of HK
OrbusNeich Medical Group Holdings's trailing twelve-month P/E ratio is 9.2x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
OrbusNeich Medical Group Holdings runs a net profit margin of 23.2%, a gross margin of 67.8%, and an operating margin of 22.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
OrbusNeich Medical Group Holdings reported revenue of
OrbusNeich Medical Group Holdings offers a trailing dividend yield of about 7.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
OrbusNeich Medical Group Holdings carries a debt-to-equity ratio of 0.01x and a current ratio of 10.54x, with a market beta of -0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For OrbusNeich Medical Group Holdings (6929) the key facts are: market cap HK
Get OrbusNeich Medical Group Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.